Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction

被引:42
作者
Cai, JC
Terasaki, PI
Bloom, DD
Torrealba, JR
Friedl, A
Sollinger, HW
Knechtle, SJ
机构
[1] Univ Wisconsin, Sch Med, Dept Surg, Madison, WI 53706 USA
[2] Terasaki Fdn Lab, Los Angeles, CA USA
[3] Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI 53706 USA
关键词
D O I
10.1097/01.tp.0000134398.86243.81
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. In this study, we determined whether Campath-1H induction followed by sirolimus monotherapy inhibited alloantibody production in renal transplantation. Second, we evaluated the correlation between human leukocyte antigen (HLA) antibody production and serum creatinine levels. Methods. Sera were taken 1 to 24 months after transplantation from 24 patients treated with Campath-1H and sirolimus and tested for serum creatinine and HLA-specific antibody by using flow cytometry and enzyme-linked immunosorbent assay. Results. Ten (42%) of the 24 patients treated with Campath-1H and sirolimus produced HLA antibodies. Six of these 10 developed both donor-specific antibodies (DSAs) and non-donor-specific antibodies (NDSAs), whereas only NDSAs were detected in the other four patients. In patients with biopsy-diagnosed humoral rejection (C4d+), serum levels of both DSA and NDSA significantly correlated with patient serum creatinine levels. Rejection treatment successfully reduced both DSAs and NDSAs and reversed humoral rejection. Conclusions. The numeric relationship between serum creatinine and DSA levels suggests a causal relationship between alloantibody and transplant rejection.
引用
收藏
页码:919 / 924
页数:6
相关论文
共 28 条
[1]
BLAZAR BR, 1994, BLOOD, V83, P600
[2]
Böhmig GA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341091
[3]
CAI J, 2003, CLIN TRANSPLANTS 200, P359
[4]
Calne R, 1998, LANCET, V352, P408
[5]
Collins AB, 1999, J AM SOC NEPHROL, V10, P2208
[6]
Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts [J].
Faulk, WP ;
Rose, M ;
Meroni, PL ;
Del Papa, N ;
Torry, RJ ;
Labarrere, CA ;
Busing, K ;
Crisp, SJ ;
Dunn, MJ ;
Nelson, DR .
HUMAN IMMUNOLOGY, 1999, 60 (09) :826-832
[7]
Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity [J].
Feucht, HE .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :646-652
[8]
Hyperacute rejection following lung transplantation [J].
Frost, AE ;
Jammal, CT ;
Cagle, PT .
CHEST, 1996, 110 (02) :559-562
[9]
Higuchi M L, 1989, Arq Bras Cardiol, V52, P39
[10]
Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H) [J].
Kirk, AD ;
Hale, DA ;
Mannon, RB ;
Kleiner, DE ;
Hoffmann, SC ;
Kampen, RL ;
Cendales, LK ;
Tadaki, DK ;
Harlan, DM ;
Swanson, SJ .
TRANSPLANTATION, 2003, 76 (01) :120-129